4 Issues to Watch after 340B Orphan Drug Ruling


David Ivill suggested that freestanding cancer hospitals might be particularly open to leaving the 340B drug program after a federal court barred certain providers from receiving 340B discounts. “They may just say to themselves, ‘If we’re not able to take advantage of 340B pricing on orphan drugs, we’re better off leaving the program,’” Mr. Ivill speculated, adding that, in any event, “the hospitals would answer that on a covered-entity-by-covered-entity basis.”